
Gastric Cancer Market
Description
Gastric Cancer Market Report and Forecast 2024-2032
The gastric cancer market was valued at USD 4.9 billion in 2023, driven by the increasing incidence of gastric cancer and increase in clinical trials and research activities across the 8 major markets. The market is projected to grow at a CAGR of 13% during the forecast period 2024-2032, with its value expected to reach USD 14.5 billion by 2032.
Gastric Cancer Market Analysis
Gastric cancer, or stomach cancer, primarily develops from the mucosal lining, with adenocarcinoma being the most common form. Often asymptomatic in its early stages, it is frequently diagnosed late. Key risk factors include Helicobacter pylori infection, a diet high in smoked or salted foods, smoking, and genetic predispositions like CDH1 mutations. As the disease progresses, symptoms such as weight loss, indigestion, nausea, and gastrointestinal bleeding may appear. Diagnosis involves endoscopy, imaging, and biomarker testing. Treatment depends on the stage and includes surgery, chemotherapy, targeted therapy, immunotherapy, and radiation, often in combination for advanced cases.
Market Drivers
The gastric cancer market is undergoing significant evolution, propelled by technological advancements and emerging treatment approaches. As ongoing research sheds light on the disease’s complexities, several important trends are emerging, which are expected to influence the future trajectory of this market.
Gastric Cancer Market Segmentation
Market Breakup by Treatment Type
Market Breakup by Cancer Type
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Gastric Cancer Market Competitive Landscape
The competitive landscape of the gastric cancer market is highly dynamic, with leading pharmaceutical companies such as AstraZeneca, Pfizer, Novartis AG, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Celltrion, AbbVie Inc., and GSK plc playing prominent roles. These companies are actively engaged in expanding their portfolios with novel therapies, particularly in the fields of immunotherapy and targeted treatments, which are gaining significant market share. Strategic collaborations, mergers, acquisitions, and licensing agreements are key strategies, aimed at accelerating innovation and enhancing patient outcomes. Ongoing clinical trials and the development of combination therapies are expected to shape the market’s future, improving access to advanced treatments.
Key Questions Answered in the Report
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the gastric cancer market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the gastric cancer market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the gastric cancer industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The gastric cancer market was valued at USD 4.9 billion in 2023, driven by the increasing incidence of gastric cancer and increase in clinical trials and research activities across the 8 major markets. The market is projected to grow at a CAGR of 13% during the forecast period 2024-2032, with its value expected to reach USD 14.5 billion by 2032.
Gastric Cancer Market Analysis
Gastric cancer, or stomach cancer, primarily develops from the mucosal lining, with adenocarcinoma being the most common form. Often asymptomatic in its early stages, it is frequently diagnosed late. Key risk factors include Helicobacter pylori infection, a diet high in smoked or salted foods, smoking, and genetic predispositions like CDH1 mutations. As the disease progresses, symptoms such as weight loss, indigestion, nausea, and gastrointestinal bleeding may appear. Diagnosis involves endoscopy, imaging, and biomarker testing. Treatment depends on the stage and includes surgery, chemotherapy, targeted therapy, immunotherapy, and radiation, often in combination for advanced cases.
Market Drivers
- Rising Global Prevalence of Gastric Cancer: The increasing incidence of gastric cancer globally, especially in high-risk areas like East Asia, is a significant driver for market growth. As the number of cases rises, there is a greater demand for advanced treatment options, including surgical procedures, targeted therapies, and immunotherapies, all contributing to market expansion. This growing patient pool is placing considerable pressure on healthcare systems to develop and implement more effective diagnostic and therapeutic solutions.
- Advancements in Diagnostic Technologies: Significant progress in diagnostic tools, such as endoscopic techniques, biomarker testing, and precision imaging, has greatly enhanced the early detection of gastric cancer. Early diagnosis is critical in improving survival rates, as treatment in the early stages of the disease is far more effective. These technological advancements have also led to the increased adoption of precision medicine, which tailors treatments to individual patients, further driving market demand for personalised therapies.
- Ageing Population: The global ageing population is a key driver for the gastric cancer market. With people living longer, there is a growing prevalence of cancer, particularly in those aged 50 and older. This demographic shift is expected to lead to a sustained rise in gastric cancer cases, necessitating the development of improved treatment options that can be effectively administered to elderly patients, who often have additional comorbidities requiring specialised care.
- Increased Focus on Immunotherapy: The growing adoption of immunotherapy in oncology, particularly with drugs such as checkpoint inhibitors, has opened up new avenues for treating gastric cancer, especially in patients with advanced or metastatic disease. Immunotherapy offers a promising alternative to traditional treatments like chemotherapy and is becoming a cornerstone in the treatment of various cancer types, including gastric cancer, thus driving demand for innovative immunotherapeutic solutions.
- Late-Stage Diagnosis: Gastric cancer is frequently diagnosed in its later stages due to non-specific early symptoms, such as indigestion and stomach discomfort, which are often mistaken for less severe conditions. This delayed diagnosis reduces the effectiveness of treatment options and contributes to lower survival rates. The late detection of the disease remains a significant challenge for the market, as it limits the success of potentially curative treatments.
- Limited Public Awareness: Despite increasing incidences of gastric cancer in some regions, public awareness of the disease remains low. Many patients are unaware of the risk factors or the importance of early screening, particularly in countries where gastric cancer is less prevalent. This lack of awareness hinders early detection efforts and reduces the potential for early intervention, thereby limiting the effectiveness of treatment and the overall market growth.
- Adverse Side Effects of Treatment: Many of the existing treatments for gastric cancer, including chemotherapy and radiotherapy, are associated with significant side effects, such as nausea, immune system suppression, and fatigue. These adverse effects often lead to poor patient adherence, reducing the overall success of treatment and presenting a challenge for market players to develop therapies that are both effective and better tolerated.
- Regulatory Hurdles and Reimbursement Issues: Varying regulatory frameworks across different countries and regions pose challenges for companies looking to launch new treatments. The complexity of securing regulatory approvals, combined with the difficulties in obtaining reimbursement for high-cost therapies, can slow down the introduction of novel drugs, limiting market growth, especially in regions with stringent healthcare regulations.
- Development of Precision Medicine: Precision medicine, which involves tailoring treatment to the genetic profile of a patient’s cancer, is emerging as a transformative approach in gastric cancer treatment. With ongoing research into the molecular mechanisms of gastric cancer, there is significant potential for the development of targeted therapies that provide more effective and personalised treatment options, thus driving the market growth.
- Collaborative Partnerships and Strategic Alliances: Increasing collaboration between pharmaceutical companies, research institutions, and academic centres is fostering innovation in the gastric cancer market. These partnerships are aimed at accelerating the development of new treatments, sharing research insights, and improving patient access to advanced therapies. Such strategic alliances present significant opportunities for market expansion and innovation.
- Growth in Early Detection Programmes: The rising emphasis on early detection of gastric cancer through government-led screening programmes and public health initiatives provides a major opportunity for market growth. Early-stage cancer detection significantly improves the chances of successful treatment, thereby increasing the demand for diagnostic tools and treatments aimed at early intervention.
- Advances in Minimally Invasive Surgical Techniques: The development of minimally invasive surgical techniques, such as laparoscopic and robotic surgeries, offers a less invasive treatment option for patients with early-stage gastric cancer. These techniques are associated with shorter recovery times, fewer complications, and improved patient outcomes, which is driving their adoption in hospitals and clinics, presenting a significant growth opportunity for the market.
The gastric cancer market is undergoing significant evolution, propelled by technological advancements and emerging treatment approaches. As ongoing research sheds light on the disease’s complexities, several important trends are emerging, which are expected to influence the future trajectory of this market.
- Rising Adoption of Targeted Therapies
- Growing Popularity of Immunotherapy
- Increasing Use of Artificial Intelligence in Diagnostics
- Surge in Clinical Trials for Combination Therapies
- Emphasis on Early Detection Initiatives
- Advancement in Surgical Techniques
Gastric Cancer Market Segmentation
Market Breakup by Treatment Type
- Chemotherapy
- Immunotherapy
- Surgery
- Targeted Drug Therapy
- Others
Market Breakup by Cancer Type
- Adenocarcinoma
- Gastrointestinal Stromal Tumor
- Carcinoid Tumor
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by End User
- Hospitals and Clinics
- Diagnostic Centers
- Research Laboratories
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Gastric Cancer Market Competitive Landscape
The competitive landscape of the gastric cancer market is highly dynamic, with leading pharmaceutical companies such as AstraZeneca, Pfizer, Novartis AG, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Celltrion, AbbVie Inc., and GSK plc playing prominent roles. These companies are actively engaged in expanding their portfolios with novel therapies, particularly in the fields of immunotherapy and targeted treatments, which are gaining significant market share. Strategic collaborations, mergers, acquisitions, and licensing agreements are key strategies, aimed at accelerating innovation and enhancing patient outcomes. Ongoing clinical trials and the development of combination therapies are expected to shape the market’s future, improving access to advanced treatments.
Key Questions Answered in the Report
- What is the current and projected growth of the gastric cancer treatment market globally and by region?
- What are the key challenges affecting the development and adoption of advanced gastric cancer treatments?
- What are the primary drivers contributing to the increasing demand for gastric cancer therapies?
- How are emerging trends like immunotherapy and targeted therapies influencing the treatment landscape for gastric cancer?
- What role does the ageing population play in driving the growth of the gastric cancer market?
- How will advancements in diagnostic technologies, such as precision imaging and biomarker identification, impact the market?
- How are hospitals and clinics adapting to the rising demand for advanced gastric cancer treatments?
- What opportunities exist for market growth in emerging regions, such as India and Southeast Asia?
- How do regulatory and reimbursement hurdles across different regions affect the introduction of novel gastric cancer therapies?
- How are pharmaceutical companies leveraging collaborations and strategic alliances to accelerate the development of gastric cancer treatments?
- What impact is precision medicine expected to have on the future of gastric cancer treatment and patient outcomes?
- How are AI and other advanced technologies transforming the diagnostic processes for early detection of gastric cancer?
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the gastric cancer market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the gastric cancer market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the gastric cancer industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Gastric Cancer Market Overview – 8 Major Markets
- 3.1 Gastric Cancer Market Historical Value (2017-2023)
- 3.2 Gastric Cancer Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Gastric Cancer Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Gastric Cancer Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Gastric Cancer Market Landscape – 8 Major Markets
- 8.1 Gastric Cancer Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Gastric Cancer Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 8.2.2 Analysis by Cancer Type
- 8.2.3 Analysis by Route of Administration
- 9 Gastric Cancer Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Gastric Cancer Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Gastric Cancer Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Gastric Cancer Market (2018-2034) by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Chemotherapy
- 12.1.3 Immunotherapy
- 12.1.4 Surgery
- 12.1.5 Targeted Drug Therapy
- 12.1.6 Others
- 12.2 Gastric Cancer Market (2018-2034) by Cancer Type
- 12.2.1 Market Overview
- 12.2.2 Adenocarcinoma
- 12.2.3 Gastrointestinal Stromal Tumor
- 12.2.4 Carcinoid Tumor
- 12.2.5 Others
- 12.3 Gastric Cancer Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.3.4 Others
- 12.4 Gastric Cancer Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals & Clinics
- 12.4.3 Diagnostic Centers
- 12.4.4 Research Laboratories
- 12.4.5 Others
- 12.5 Gastric Cancer Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Gastric Cancer Market (2018-2034)
- 13.1 United States Gastric Cancer Market Historical Value (2017-2023)
- 13.2 United States Gastric Cancer Market Forecast Value (2024-2032)
- 13.3 United States Gastric Cancer Market (2018-2034) by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Chemotherapy
- 13.3.3 Immunotherapy
- 13.3.4 Surgery
- 13.3.5 Targeted Drug Therapy
- 13.3.6 Others
- 13.4 United States Gastric Cancer Market (2018-2034) by Cancer Type
- 13.4.1 Market Overview
- 13.4.2 Adenocarcinoma
- 13.4.3 Gastrointestinal Stromal Tumor
- 13.4.4 Carcinoid Tumor
- 13.4.5 Others
- 13.5 United States Gastric Cancer Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 13.5.4 Others
- 13.6 United States Gastric Cancer Market (2018-2034) by End User
- 13.6.1 Market Overview
- 13.6.2 Hospitals & Clinics
- 13.6.3 Diagnostic Centers
- 13.6.4 Research Laboratories
- 13.6.5 Others
- 14 EU-4 and United Kingdom Gastric Cancer Market (2018-2034)
- 14.1 EU-4 and United Kingdom Gastric Cancer Market Historical Value (2017-2023)
- 14.2 EU-4 and United Kingdom Gastric Cancer Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Gastric Cancer Market (2018-2034) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Chemotherapy
- 14.3.3 Immunotherapy
- 14.3.4 Surgery
- 14.3.5 Targeted Drug Therapy
- 14.3.6 Others
- 14.4 EU-4 and United Kingdom Gastric Cancer Market (2018-2034) by Cancer Type
- 14.4.1 Market Overview
- 14.4.2 Adenocarcinoma
- 14.4.3 Gastrointestinal Stromal Tumor
- 14.4.4 Carcinoid Tumor
- 14.4.5 Others
- 14.5 EU-4 and United Kingdom Gastric Cancer Market (2018-2034) by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Parenteral
- 14.5.4 Others
- 14.6 EU-4 and United Kingdom Gastric Cancer Market (2018-2034) by End User
- 14.6.1 Market Overview
- 14.6.2 Hospitals & Clinics
- 14.6.3 Diagnostic Centers
- 14.6.4 Research Laboratories
- 14.6.5 Others
- 15 Japan Gastric Cancer Market
- 15.1 Japan Gastric Cancer Market Historical Value (2017-2023)
- 15.2 Japan Gastric Cancer Market Forecast Value (2024-2032)
- 15.3 Japan Gastric Cancer Market (2018-2034) by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Chemotherapy
- 15.3.3 Immunotherapy
- 15.3.4 Surgery
- 15.3.5 Targeted Drug Therapy
- 15.3.6 Others
- 15.4 Japan Gastric Cancer Market (2018-2034) by Cancer Type
- 15.4.1 Market Overview
- 15.4.2 Adenocarcinoma
- 15.4.3 Gastrointestinal Stromal Tumor
- 15.4.4 Carcinoid Tumor
- 15.4.5 Others
- 15.5 Japan Gastric Cancer Market (2018-2034) by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Oral
- 15.5.3 Parenteral
- 15.5.4 Others
- 15.6 Japan Gastric Cancer Market (2018-2034) by End User
- 15.6.1 Market Overview
- 15.6.2 Hospitals & Clinics
- 15.6.3 Diagnostic Centers
- 15.6.4 Research Laboratories
- 15.6.5 Others
- 16 India Gastric Cancer Market
- 16.1 India Gastric Cancer Market Historical Value (2017-2023)
- 16.2 India Gastric Cancer Market Forecast Value (2024-2032)
- 16.3 India Gastric Cancer Market (2018-2034) by Treatment Type
- 16.3.1 Market Overview
- 16.3.2 Chemotherapy
- 16.3.3 Immunotherapy
- 16.3.4 Surgery
- 16.3.5 Targeted Drug Therapy
- 16.3.6 Others
- 16.4 India Gastric Cancer Market (2018-2034) by Cancer Type
- 16.4.1 Market Overview
- 16.4.2 Adenocarcinoma
- 16.4.3 Gastrointestinal Stromal Tumor
- 16.4.4 Carcinoid Tumor
- 16.4.5 Others
- 16.5 India Gastric Cancer Market (2018-2034) by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Oral
- 16.5.3 Parenteral
- 16.5.4 Others
- 16.6 India Gastric Cancer Market (2018-2034) by End User
- 16.6.1 Market Overview
- 16.6.2 Hospitals & Clinics
- 16.6.3 Diagnostic Centers
- 16.6.4 Research Laboratories
- 16.6.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Cancer Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Treatment Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Treatment Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 AstraZeneca
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Companies News and Developments
- 23.2.5 Certifications
- 23.3 Pfizer, Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Companies News and Developments
- 23.3.5 Certifications
- 23.4 Novartis AG
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Companies News and Developments
- 23.4.5 Certifications
- 23.5 Amgen Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Companies News and Developments
- 23.5.5 Certifications
- 23.6 Bristol-Myers Squibb Company
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Companies News and Developments
- 23.6.5 Certifications
- 23.7 Eli Lily and Company
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Companies News and Developments
- 23.7.5 Certifications
- 23.8 Celltrion
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Companies News and Developments
- 23.8.5 Certifications
- 23.9 AbbVie Inc
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Companies News and Developments
- 23.9.5 Certifications
- 23.10 GSK plc
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Companies News and Developments
- 23.10.5 Certifications
- 24 Gastric Cancer Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- *The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.